On Tuesday, Nektar Therapeutics (NASDAQ: NKTR) opened lower -5.65% from the last session, before settling in for the closing price of $38.77. Price fluctuations for NKTR have ranged from $0.43 to $66.92 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 25.49% over the past five years. Company’s average yearly earnings per share was noted -14.85% at the time writing. With a float of $20.04 million, this company’s outstanding shares have now reached $20.34 million.
Nektar Therapeutics (NKTR) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nektar Therapeutics is 1.48%, while institutional ownership is 70.44%. The most recent insider transaction that took place on Nov 25 ’25, was worth 62,802. In this transaction Chief R&D Officer of this company sold 1,157 shares at a rate of $54.28, taking the stock ownership to the 18,971 shares. Before that another transaction happened on Nov 25 ’25, when Company’s Chief Legal Officer sold 630 for $54.28, making the entire transaction worth $34,196. This insider now owns 21,585 shares in total.
Nektar Therapeutics (NKTR) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -2.25 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -2.92) by 0.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.99% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Check out the current performance indicators for Nektar Therapeutics (NKTR). In the past quarter, the stock posted a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.94, a number that is poised to hit -2.41 in the next quarter and is forecasted to reach -9.79 in one year’s time.
